In Cephalon, Teva Will Get An Expanded Innovative R&D And Branded Portfolio
By
Wendy Diller / Email the Author / “The Pink Sheet” DAILY May 3, 2011
Word Count: 1695 / Article # 14110502004
Executive Summary
The giant Israeli generics firm extols Cephalon's R&D but the deal's real value may be more nuanced: a combination of cost synergies, late-stage pipeline assets, and expansion of Teva's mix of branded products in anticipation of upcoming challenges in both the branded and generics businesses.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.